Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
Public ClinicalTrials.gov record NCT05436535. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (ADRN-12)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected at all study visits to determine the gene expression profiles and transcriptomic endotypes that underlie mild vs. moderate-severe AD disease. The investigators will also evaluate the lipidomic, metabolomic, proteomic, and microbiome profiles of AD skin endotypes associated with mild and moderate-severe AD disease. Non-AD participants will serve as a control population. The primary objective of this study is to determine if the type 2-high non-lesional skin (skin tape) endotype is associated with current mild versus moderate-severe AD disease.
Study identification
- NCT ID
- NCT05436535
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 433 participants
Conditions and interventions
Conditions
Interventions
- Dupilumab Biological
- Vanicream- Dupilumab-naïve Drug
- Triamcinolone Acetonide Drug
- Hydrocortisone Drug
- Vanicream- Active Drug
- Vanicream- Experienced Dupilumab Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 6 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 21, 2022 (Actual)
- Primary completion
- Apr 7, 2025 (Actual)
- Completion
- Oct 24, 2025 (Actual)
- Last update posted
- Jun 4, 2026
2022 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego: Dermatology Clinical Trials Unit | La Jolla | California | 92093 | — |
| Children's Hospital Los Angeles: Division of Clinical Immunology & Allergy | Los Angeles | California | 90027 | — |
| National Jewish Health: Division of Pediatric Allergy and Clinical Immunology | Denver | Colorado | 80206 | — |
| Boston Children's Hospital: Department of Immunology | Boston | Massachusetts | 02215 | — |
| Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology | New York | New York | 10029 | — |
| University of Rochester Medical Center: Department of Dermatology | Rochester | New York | 14642 | — |
| North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology | Chapel Hill | North Carolina | 27599 | — |
| Cincinnati Children's Hospital Medical Center: Asthma Center | Cincinnati | Ohio | 45229 | — |
| Oregon Health & Science University: Department of Dermatology | Portland | Oregon | 97239 | — |
| University of Pennsylvania, Perelman Center for Advanced Medicine: Department of Dermatology | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05436535, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05436535 live on ClinicalTrials.gov.